Commentary by Cara Litvin MD, Executive Editor, Clinical Correlations
I frowned as my patient handed over some papers to me at a regularly scheduled follow-up clinic visit. For the second time in a row, he had …
Commentary by Cara Litvin MD, Executive Editor, Clinical Correlations
I frowned as my patient handed over some papers to me at a regularly scheduled follow-up clinic visit. For the second time in a row, he had …
Commentary by Zackary Berger MD PhD, PGY-2
In the political arena, reforming health care is continually a major domestic issue. It’s no surprise that the lead 2008 democratic contenders cite the same statistic on …
Commentary by Vlad Fridman MD, PGY-2
$50,000. This is the price of a new (and cheap) model BMW, and also a price the US government is willing to spend to prolong your medically trained (or everyone else’s for that …
Welcome to our first blog commentary. One of the purposes of the blog is to generate discussion about issues in health care. This “Clinical Commentary” section is an invitation to our housestaff and faculty to submit their own thoughts and viewpoints on …
The debate about the ethically questionable relationship between physicians and the pharmaceutical industry opened up again this morning on the front page of the New York Times. Although the article is heavy on interview and anecdote and a little short on evidence, …
Commentary By: Sandeep Mangalmurti MD, JD PGY-1
The continuing legal battles over Vioxx remain at the center of a fascinating intersection of law and medicine. Most physicians are well acquainted with the basics of the case, but like most …
Commentary By: Sandeep Mangalmurti, MD, JD PGY-1
For many physicians, medical malpractice is like paying taxes; inevitable, but incomprehensible. This is unfortunate, since most physicians offer unique insights into the current debate on malpractice reform. Hopefully this article will begin …
In the summer of 2002, I worked in DC for the Pharmaceutical Researchers and Manufacturers of America (PHRMA), which is an umbrella organization that represents the largest pharmaceutical companies. It was …